The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Targeting pathological B cell receptor signalling in lymphoid malignancies
Open accessAbstract
Signalling through the B cell receptor (BCR) is central to the development and maintenance of B cells. In light of the numerous proliferative and survival pathways activated downstream of the BCR, it comes as no surprise that malignant B cells would co-opt this receptor to promote their own growth and survival. However, direct evidence for BCR signalling in human lymphoma has only come to light recently. Roles for antigen-dependent and antigen-independent, or tonic, BCR signalling have now been described for several different lymphoma subtypes. Furthermore, correlative data implicate antigen-dependent BCR signalling in many other forms of lymphoma. A host of therapeutic agents targeting effectors of the BCR signalling pathway are now in clinical trials and have shown initial success against multiple forms of lymphoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Victora, G. D., & Nussenzweig, M. C. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075032 · Cited by 1,878
BRUTON, O. C. (1952) · Pediatrics · doi:10.1542/peds.9.6.722 · Cited by 1,492
The SYK tyrosine kinase: A crucial player in diverse biological functions
Mócsai, A., Ruland, J., & Tybulewicz, V. L. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2765 · Cited by 1,368
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128
CARMA1, BCL-10 and MALT1 in lymphocyte development and activation
Thome, M. (2004) · Nature Reviews Immunology · doi:10.1038/nri1352 · Cited by 391
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
Hantschel, O., Rix, U., Schmidt, U., Bürckstümmer, T., Kneidinger, M., Schütze, G., Colinge, J., Bennett, K. L., Ellmeier, W., Valent, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702654104 · Cited by 284
Prostate Stem Cell Antigen Is Overexpressed in Prostate Cancer Metastases
Lam, J. S., Yamashiro, J., Shintaku, I. P., Vessella, R. L., Jenkins, R. B., Horvath, S., Said, J. W., & Reiter, R. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1842 · Cited by 211
Gobessi, S., Laurenti, L., Longo, P. G., Carsetti, L., Berno, V, Sica, S., Leone, G., & Efremov, D. G. (2009) · Leukemia · doi:10.1038/leu.2008.346 · Cited by 200
Watanabe, D., Hashimoto, S., Ishiai, M., Matsushita, M., Baba, Y., Kishimoto, T., Kurosaki, T., & Tsukada, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103675200 · Cited by 136
Activation of Phospholipase Cγ2 by Tyrosine Phosphorylation
Özdener, F., Dangelmaier, C., Ashby, B., Kunapuli, S. P., & Daniel, J. L. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.3.672 · Cited by 60
Cited by
Targeting B cell receptor signalling in cancer: preclinical and clinical advances
Burger, J. A., & Wiestner, A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.121 · Cited by 431
B cell receptor signaling in chronic lymphocytic leukemia
Burger, J. A., & Chiorazzi, N. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.002 · Cited by 327
Chiron, D., Di Liberto, M., Martin, P., Huang, X., Sharman, J., Blecua, P., Mathew, S., Vijay, P., Eng, K., Ali, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0098 · Cited by 273
Xiao, G., Chan, L. N., Klemm, L., Braas, D., Chen, Z., Geng, H., Zhang, Q. C., Aghajanirefah, A., Cosgun, K. N., Sadras, T., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.048 · Cited by 129
Casein kinase 1α: biological mechanisms and theranostic potential
Jiang, S., Zhang, M., Sun, J., & Yang, X. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0236-z · Cited by 130
Systems‐wide analysis of BCR signalosomes and downstream phosphorylation and ubiquitylation
Satpathy, S., Wagner, S. A., Beli, P., Gupta, R., Kristiansen, T. A., Malinova, D., Francavilla, C., Tolar, P., Bishop, G. A., Hostager, B. S., et al. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145880 · Cited by 124
NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms
Yu, L., Li, L., Medeiros, L. J., & Young, K. H. (2017) · Blood Reviews · doi:10.1016/j.blre.2016.10.001 · Cited by 105
Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells
Ma, J., Lu, P., Guo, A., Cheng, S., Zong, H., Martin, P., Coleman, M., & Wang, Y. L. (2014) · British Journal of Haematology · doi:10.1111/bjh.12974 · Cited by 90
Phosphatidylserine synthesis controls oncogenic B cell receptor signaling in B cell lymphoma
Omi, J., Kato, T., Yoshihama, Y., Sawada, K., Kono, N., & Aoki, J. (2024) · Journal of Cell Biology · doi:10.1083/jcb.202212074 · Cited by 18
Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma
Yan, X., Zhou, Y., Huang, S., Li, X., Yu, M., Huang, J., Wang, J., Ma, Z., Jin, J., Pan, J., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2570-8 · Cited by 12
Expression and pro-survival function of phospholipase Cγ2 in diffuse large B-cell lymphoma
Huynh, M. Q., Goßmann, J., Gattenlöehner, S., Klapper, W., Wacker, H.-H., Ramaswamy, A., Bittner, A., Kaiser, U., & Neubauer, A. (2015) · Leukemia & Lymphoma · doi:10.3109/10428194.2014.941832 · Cited by 8
Metadata
- Authors
- Young, R. M., & Staudt, L. M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2013-03
- Volume
- 12
- Issue
- 3
- Pages
- 229-243
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2067257663
- Cited by
- 401
- References
- 10
- FWCI
- 8.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
